DUBLIN, Oct. 31, 2023 /PRNewswire/ -- The 'Global Precision Medicine Business Investment Opportunities' report is now available at ResearchAndMarkets.com. This report furnishes a data-centric perspective on the burgeoning precision medicine industry, emphasizing its potential, growth trajectory, and influential trends..

都柏林，2023年10月31日/PRNewswire/-“全球精准医药商业投资机会”报告现已在ResearchAndMarkets.com上发布。本报告对新兴的精准医药行业提供了以数据为中心的观点，强调了其潜力，增长轨迹和有影响力的趋势。。

Precision medicine is redefining healthcare, equipping medical professionals with tools to predict disease risk, make accurate diagnoses, and devise customized treatment plans. The report underscores that its application is not just a North American phenomenon. For instance, global initiatives such as the UK Biobank and BioBank Japan echo the paradigm shift towards precision medicine..

精准医学正在重新定义医疗保健，为医疗专业人员提供预测疾病风险，做出准确诊断和制定定制治疗计划的工具。该报告强调，其应用不仅仅是北美现象。例如，英国生物银行和日本生物银行等全球倡议呼应了精准医学的范式转变。。

While the allure of AI and precision medicine is palpable, challenges remain, particularly in data harmonization and meeting regulatory, privacy, and sociocultural mandates.

虽然人工智能和精准医学的吸引力是显而易见的，但挑战依然存在，特别是在数据协调和满足监管，隐私和社会文化要求方面。

Key Highlights:

主要亮点：

Precision Medicine market is projected to grow at a CAGR of 11.3% from 2023 to 2027, reaching a valuation of US$126.481 billion by 2027.

精准医药市场预计从2023年到2027年将以11.3%的CAGR增长，到2027年达到1264.81亿美元的估值。

Increasing prevalence of chronic diseases, demand for personalized medicine, and technological breakthroughs are driving this growth.

慢性病患病率增加，个性化医疗需求和技术突破正在推动这一增长。

The oncology segment is predicted to command the largest market share, powered by precision medicine's transformative role in cancer treatment.

预计肿瘤学领域将占据最大的市场份额，由精准医学在癌症治疗中的变革作用推动。

Big data analytics, notably the tool developed by the University of Michigan Rogel Cancer Center, are revolutionizing the precision medicine landscape.

大数据分析，特别是密歇根大学罗格尔癌症中心开发的工具，正在彻底改变精准医学领域。

Collaborations and acquisitions, such as the partnership between Kaiku Health and Novartis and the acquisition by Stalicla, underline industry dynamism.

合作和收购，例如凯库健康与诺华之间的合作关系以及Stalicla的收购，强调了行业活力。

Spotlight on Market Dynamics:

市场动态聚光灯：

Invitae has obtained commercial coverage approval from Blue Shield of California for its Personalized Cancer Monitoring (PCMT) assay, marking a significant development in post-surgical cancer treatment monitoring.

Invitae已获得加利福尼亚州Blue Shield的商业覆盖批准，用于其个性化癌症监测（PCMT）检测，标志着手术后癌症治疗监测的重大发展。

Invitae and Epic have joined forces. Leveraging Epic's diagnostic suite, Aura, the collaboration will expedite the provision of genetic insights to inform treatment decisions within the Epic ecosystem.

Invitae和Epic已经加入。利用Epic的诊断套件Aura，该合作将加快提供遗传见解，为Epic生态系统内的治疗决策提供信息。

Stalicla has acquired rights from Novartis to develop the drug mavoglurant, earmarked for substance use and neurodevelopmental disorders.

Stalicla已获得诺华公司开发药物mavoglurant的权利，该药物专门用于物质使用和神经发育障碍。

Deep Dive into Research Initiatives:

深入研究研究计划：

Recent introductions to the research landscape include the IGNITE program, championing the integration of genomic studies in clinical practice, and CSER-2, funded by the NHGRI and NCI, to embed genomic sequencing in clinical settings.

最近对研究领域的介绍包括支持将基因组研究整合到临床实践中的IGNITE计划，以及由NHGRI和NCI资助的CSER-2，以将基因组测序嵌入临床环境。

Precision Medicine: Segmented Analysis

精准医学：分段分析

The report segments the precision medicine market across various parameters, from technology platform, drug types, and sequencing technology to end-users. These insights encompass market share analyses by region, covering North America, Europe, Asia-Pacific, and more, and by key players in the industry, such as Bayer AG, BioNTech SE, and Moderna, Inc..

该报告通过各种参数将精准医药市场细分，从技术平台，药物类型和测序技术到最终用户。这些见解包括按地区划分的市场份额分析，涵盖北美，欧洲，亚太地区等，以及拜耳公司，BioNTech SE和Moderna，Inc等行业的主要参与者。。

The report's design offers clarity, categorizing the insights into six modules: Investment Landscape, Clinical Trial Data, Patent Data Analysis, Competitive Landscape, Market Size and Forecast, and Regulatory Outlook.

该报告的设计提供了清晰的信息，将见解分为六个模块：投资格局，临床试验数据，专利数据分析，竞争格局，市场规模和预测以及监管前景。

Potential stakeholders will gain an in-depth understanding of market dynamics, competitive landscapes, clinical trials, precision medicine patents, financial deals, and strategic insights.

潜在的利益相关者将深入了解市场动态，竞争格局，临床试验，精准药物专利，金融交易和战略见解。

For more information about this report visit https://www.researchandmarkets.com/r/kvrvl7

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/kvrvl7

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

关于ResearchAndMarkets.com ResearchAndMarkets.com是国际市场研究报告和市场数据的全球领先来源。我们为您提供有关国际和区域市场，关键行业，顶级公司，新产品和最新趋势的最新数据。

Media Contact:

媒体联系：

Research and MarketsLaura Wood, Senior Manager[email protected]    For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

研究和市场高级经理[电子邮件保护]E.S.T办公时间致电+1-917-300-0470美国/CAN免费致电+1-800-526-8630 GMT办公时间致电+353-1-416-8900美国传真：646-607-1907传真（美国境外）：+353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

标志：https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

来源研究和市场